top of page
23 avr. 2026
Aton Group highlights B Cell Design, a portfolio company leveraging patented monoclonal antibody technology to address growing demand in the in vitro diagnostics market.
Illkirch, France, April 23, 2026, specialized in life sciences and medical technologies, is publishing this fifth press release in a series dedicated to the positioning of its subsidiaries. This edition highlights B Cell Design, a portfolio company developing and producing human Fc monoclonal antibodies for the in vitro diagnostics (IVD) industry—an asset whose value is built on patented technology, a structurally growing market, and a commercial momentum currently being deployed..
Download ATON press release
bottom of page